PURPOSE:Peak oxygen consumption (VO(2peak)) is an important predictive factor for long-term prognosis in patients with non-small cell lung cancer (NSCLC). The purpose of this study was to investigate whether 8 weeks of exercise training improves exercise capacity, as assessed by VO(2peak), and other related factors in patients with NSCLC receiving targeted therapy. METHODS: A total of 24 participants with adenocarcinoma were randomly assigned to either the control group (n = 11) or the exercise group (n = 13). Subjects in the exercise group participated in individualized, high-intensity aerobic interval training of exercise. The outcome measures assessed at baseline and after 8 weeks were as follows: VO(2peak) and the percentage of predicted VO(2peak) (%predVO(2peak)), muscle strength and endurance of the right quadriceps, muscle oxygenation during exercise, insulin resistance as calculated by the homeostasis model, high-sensitivity C-reactive protein, and quality of life (QoL) questionnaire inventory. RESULTS: No exercise-related adverse events were reported. After exercise training, VO(2peak) and %predVO(2peak) increased by 1.6 mL kg(-1) min(-1) and 5.3% (p < 0.005), respectively; these changes were associated with improvements in circulatory, respiratory, and muscular functions at peak exercise (all p = 0.001). The exercise group also had less dyspnea (p = 0.01) and favorably lower fatigue (p = 0.05) than baseline. CONCLUSIONS:Patients with NSCLC receiving targeted therapy have quite a low exercise capacity, even with a relatively high QoL. Exercise training appears to improve exercise capacity and alleviate some cancer-related symptoms.
RCT Entities:
PURPOSE: Peak oxygen consumption (VO(2peak)) is an important predictive factor for long-term prognosis in patients with non-small cell lung cancer (NSCLC). The purpose of this study was to investigate whether 8 weeks of exercise training improves exercise capacity, as assessed by VO(2peak), and other related factors in patients with NSCLC receiving targeted therapy. METHODS: A total of 24 participants with adenocarcinoma were randomly assigned to either the control group (n = 11) or the exercise group (n = 13). Subjects in the exercise group participated in individualized, high-intensity aerobic interval training of exercise. The outcome measures assessed at baseline and after 8 weeks were as follows: VO(2peak) and the percentage of predicted VO(2peak) (%predVO(2peak)), muscle strength and endurance of the right quadriceps, muscle oxygenation during exercise, insulin resistance as calculated by the homeostasis model, high-sensitivity C-reactive protein, and quality of life (QoL) questionnaire inventory. RESULTS: No exercise-related adverse events were reported. After exercise training, VO(2peak) and %predVO(2peak) increased by 1.6 mL kg(-1) min(-1) and 5.3% (p < 0.005), respectively; these changes were associated with improvements in circulatory, respiratory, and muscular functions at peak exercise (all p = 0.001). The exercise group also had less dyspnea (p = 0.01) and favorably lower fatigue (p = 0.05) than baseline. CONCLUSIONS:Patients with NSCLC receiving targeted therapy have quite a low exercise capacity, even with a relatively high QoL. Exercise training appears to improve exercise capacity and alleviate some cancer-related symptoms.
Authors: Eleni Th Petridou; Theodoros N Sergentanis; Constantine N Antonopoulos; Nick Dessypris; Ioannis L Matsoukis; Konstantinos Aronis; Anna Efremidis; Constantinos Syrigos; Christos S Mantzoros Journal: Metabolism Date: 2011-01-19 Impact factor: 8.694
Authors: Thida Win; Arlene Jackson; Linda Sharples; Ashley M Groves; Francis C Wells; Andrew J Ritchie; Clare M Laroche Journal: Chest Date: 2005-04 Impact factor: 9.410
Authors: Andrew Wilcock; Matthew Maddocks; Mary Lewis; Paul Howard; Jacky Frisby; Sarah Bell; Bisharat El Khoury; Cathann Manderson; Helen Evans; Simon Mockett Journal: BMC Palliat Care Date: 2008-04-10 Impact factor: 3.234
Authors: Hendrik Mugele; Nils Freitag; Jannik Wilhelmi; Yanxiang Yang; Sulin Cheng; Wilhelm Bloch; Moritz Schumann Journal: J Cancer Surviv Date: 2019-02-26 Impact factor: 4.442
Authors: Wiebke Jensen; Freerk T Baumann; Alexander Stein; Wilhelm Bloch; Carsten Bokemeyer; Maike de Wit; Karin Oechsle Journal: Support Care Cancer Date: 2014-02-15 Impact factor: 3.603